ANXA5 and neoplasm: In vivo study shows that HMSeN@HOMV plus LI could induce burst release of ANX5 to block PtdSer exposure on the membrane of dying 4T1 tumor cells, and thus reverse anti‐inflammatory M2‐like TAMs toward pro‐inflammatory M1 phenotype, which also led to potent inhibition of immunosuppressive MDSCs and Tregs, as well as, activation of DCs and tumor‐specific T cell immunity.